MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website remusclehealth.com; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone973-509-0444
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$360,000.00
Profitability
Miscellaneous
Employees12
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable
MYOS (NASDAQ:MYOS) Frequently Asked Questions
What is MYOS's stock symbol?
MYOS trades on the NASDAQ under the ticker symbol "MYOS."
How were MYOS's earnings last quarter?
MYOS Co. (NASDAQ:MYOS) released its earnings results on Thursday, November, 7th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. The company earned $0.35 million during the quarter, compared to the consensus estimate of $0.23 million. MYOS had a negative return on equity of 97.69% and a negative net margin of 391.02%. View MYOS's Earnings History.
When is MYOS's next earnings date?
Has MYOS been receiving favorable news coverage?
Media coverage about MYOS stock has trended somewhat positive recently, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MYOS earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for MYOS.
Are investors shorting MYOS?
MYOS saw a decline in short interest in December. As of December 31st, there was short interest totalling 54,900 shares, a decline of 10.0% from the December 15th total of 61,000 shares. Based on an average trading volume of 11,600 shares, the short-interest ratio is currently 4.7 days. Currently, 1.1% of the company's shares are short sold. View MYOS's Current Options Chain.
Who are some of MYOS's key competitors?
Some companies that are related to MYOS include resTORbio (TORC), DiaMedica Therapeutics (DMAC), Vascular Biogenics (VBLT), Hoth Therapeutics (HOTH), SUMMIT THERAPEU/S (SMMT), Adamis Pharmaceuticals (ADMP), Iterum Therapeutics (ITRM), Zafgen (ZFGN), Jaguar Health (JAGX), IntelGenx Technologies (IGXT), Q BioMed (QBIO), Moleculin Biotech (MBRX), Acer Therapeutics (ACER), Forward Pharma A/S (FWP) and Merrimack Pharmaceuticals (MACK).
What other stocks do shareholders of MYOS own?
Who are MYOS's key executives?
MYOS's management team includes the folowing people:
- Mr. Joseph Mannello, CEO & Director (Age 61)
- Mr. Ren Ren, Global Chairman (Age 57)
- Mr. Joseph DiPietro, Controller
- Mr. Magshoud Dariani, Chief Technology Officer
- Mr. Kris Ohrenick, Head of Marketing
How do I buy shares of MYOS?
Shares of MYOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is MYOS's stock price today?
One share of MYOS stock can currently be purchased for approximately $1.45.
How big of a company is MYOS?
MYOS has a market capitalization of $13.31 million and generates $360,000.00 in revenue each year. The company earns $-3,220,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis. MYOS employs 12 workers across the globe.View Additional Information About MYOS.
What is MYOS's official website?
How can I contact MYOS?
MYOS's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at 973-509-0444 or via email at [email protected]
MarketBeat Community Rating for MYOS (NASDAQ MYOS)
MarketBeat's community ratings are surveys of what our community members think about MYOS and other stocks. Vote "Outperform" if you believe MYOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
